Novartis' decision to buy gene therapy developer AveXis will have a crossover impact on Biogen, an early leader in the treatment market for spinal muscular atrophy (SMA) with Spinraza.
After Novartis AG announced plans to buy the gene therapy developer AveXis Inc. April 9 for $8.7bn, some Biogen investors were left wondering if Biogen shouldn't have been the acquirer instead. Now, Biogen will likely face a deep-pocked big pharma rival in the rare disease market it has dominated since the launch of Spinraza (nusinersen) in late 2016.
Spinraza has morphed into a more pivotal product to Biogen than many investors predicted, particularly as the big biotech's multiple...
Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.
GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut
The biotech had been looking at options to survive since May.
Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
